Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.49 |
| ▸ | MMP14 | P50281 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.49 |
| ▸ | METAP2 | P50579 | 2/20 | 0.49 |
| ▸ | METAP1 | P53582 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30393983 | 1.00 | MAPT (0.49) | MAPTKDM4ELMNAALDH1A1HSP90AA1 | |
| SCHEMBL7712335 | 0.80 | NR4A2 (0.67) | MAPTKDM4ELMNAALDH1A1HSP90AA1 | |
| SCHEMBL18848333 | 0.80 | KDM4E (0.48) | MAPTKDM4ELMNAALDH1A1HSP90AA1 | |
| SCHEMBL29702168 | 0.80 | NR4A2 (0.67) | MAPTKDM4ELMNAALDH1A1HSP90AA1 | |
| SCHEMBL30908289 | 0.77 | NR4A2 (0.49) | MAPTKDM4ELMNAALDH1A1HSP90AA1 | |
| SCHEMBL4433754 | 0.77 | NR4A2 (0.58) | MAPTKDM4ELMNAALDH1A1HSP90AA1 | |
| SCHEMBL17838999 | 0.77 | NR4A2 (0.49) | MAPTKDM4ELMNAALDH1A1HSP90AA1 | |
| SCHEMBL3454205 | 0.77 | NR4A2 (0.49) | MAPTKDM4ELMNAALDH1A1HSP90AA1 | |
| SCHEMBL18572649 | 0.77 | KDM4E (0.53) | MAPTKDM4ELMNAALDH1A1HSP90AA1 | |
| SCHEMBL17839007 | 0.77 | NR4A2 (0.49) | MAPTKDM4ELMNAALDH1A1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117241781-A | Loading of alginate microspheres | 德克萨斯大学系统董事会 | 2023-12-15 | — | — | CN | disclosed |
| EP-4029518-A1 | COMBINATIONAL USES OF NITROXOLINE AND ITS ANALOGUES WITH CHEMOTHERAPIES AND IMMUNOTHERAPIES IN THE TREATMENT OF CANCERS | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2022-07-20 | — | — | EP | disclosed |
| EP-4029517-A1 | COMBINATIONAL USES OF NITROXOLINE AND ITS ANALOGUES WITH CHEMOTHERAPIES AND IMMUNOTHERAPIES IN THE TREATMENT OF CANCERS | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2022-07-20 | — | — | EP | disclosed |
| US-20220218691-A1 | COMBINATIONAL USES OF NITROXOLINE AND ITS ANALOGUES WITH CHEMOTHERAPIES AND IMMUNOTHERAPIES IN THE TREATMENT OF CANCERS | ASIERIS PHARMACEUTICAL TECHNOLOGIES CO., LTD. (VG) | 2022-07-14 | — | — | US | disclosed |
| US-20220218692-A1 | COMBINATIONAL USES OF NITROXOLINE AND ITS ANALOGUES WITH CHEMOTHERAPIES AND IMMUNOTHERAPIES IN THE TREATMENT OF CANCERS | ASIERIS PHARMACEUTICAL TECHNOLOGIES CO., LTD. (VG) | 2022-07-14 | — | — | US | disclosed |
| US-11324739-B2 | Combinational uses of nitroxoline and its analogues with chemotherapies and immunotherapies in the treatment of cancers | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| US-20190275025-A1 | COMBINATIONAL USES OF NITROXOLINE AND ITS ANALOGUES WITH CHEMOTHERAPIES AND IMMUNOTHERAPIES IN THE TREATMENT OF CANCERS | PAN-SCIENTIFIC HOLDINGS CO., LTD. (VG) | 2019-09-12 | — | — | US | disclosed |
| EP-3436071-A1 | COMBINATIONAL USES OF NITROXOLINE AND ITS ANALOGUES WITH CHEMOTHERAPEIS AND IMMUNOTHERAPIES IN THE TREATMENT OF CANCERS | Asieris Pharmaceutical Technologies Co., Ltd. (VG) | 2019-02-06 | — | — | EP | disclosed |
| WO-2017173278-A1 | COMBINATIONAL USES OF NITROXOLINE AND ITS ANALOGUES WITH CHEMOTHERAPEIS AND IMMUNOTHERAPIES IN THE TREATMENT OF CANCERS | ASIERIS PHARMACEUTICAL TECHNOLOGIES CO., LTD. (VG) | 2017-10-05 | — | — | WO | disclosed |
| US-9758484-B2 | Base addition salts of nitroxoline and uses thereof | ASIERIS PHARMACEUTICAL TECHNOLOGIES CO., LTD. (CN) | 2017-09-12 | — | — | US | disclosed |
| US-20160031819-A1 | BASE ADDITION SALTS OF NITROXOLINE AND USES THEREOF | PAN-SCIENTIFIC HOLDINGS CO., LTD. (VG) | 2016-02-04 | — | — | US | disclosed |
| EP-2970128-A1 | BASE ADDITION SALTS OF NITROXOLINE AND USES THEREOF | Asieris Pharmaceutical Technologies Co., Ltd. (CN) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014145723-A1 | BASE ADDITION SALTS OF NITROXOLINE AND USES THEREOF | PAN KE (US) | 2014-09-18 | — | — | WO | disclosed |
| CN-1681791-B | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LTD | 2013-03-27 | — | — | CN | disclosed |
| WO-2001082911-A2 | TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING CLIOQUINOL | GEROLYMATOS P N SA (GR) | 2001-11-08 | — | — | WO | disclosed |
| US-6001852-A | AND AN AMOUNT OF VITAMIN B.SUB.12 EFFECTIVE TO INHIBIT A DETRIMENTAL SIDE EFFECT | P.N. GEROLYMATOS S.A. (GR) | 1999-12-14 | — | — | US | disclosed |
| US-5994323-A | SYNERGISTIC MIXTURE; ALZHEIMER'S, PARKINSON'S DISEASE | P.N. GEROLYMATOS S.A. (GR) | 1999-11-30 | — | — | US | disclosed |
| US-5980914-A | ADMINISTERING AN AMOUNT OF CLIOQUINOL WITH VITAMIN B12 EFFECTIVE TO TREAT OR DELAY THE ONSET OF PARKINSON'S DISEASE | P.N. GEROLYMATOS S.A. (GR) | 1999-11-09 | — | — | US | disclosed |
| WO-1999034807-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CLIOQUINOL AND VITAMIN B¿12? | P.N. GEROLYMATOS S.A. (GR) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031819-A1 | BASE ADDITION SALTS OF NITROXOLINE AND USES THEREOF | SLC28A1, SLC28A2, NNT | MAPT 1375/4885KDM4E 4309/4885LMNA 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.